title: Comparative in vitro metabolism of phospho-tyrosol-indomethacin by mice, rats and humans.
abstract: Phospho-tyrosol-indomethacin (PTI; MPI 621), a novel anti-cancer agent, is more potent and safer than conventional indomethacin. Here, we show that PTI was extensively metabolized in vitro and in vivo. PTI was rapidly hydrolyzed by carboxylesterases to generate indomethacin as its major metabolite in the liver microsomes and rats. PTI additionally undergoes cytochromes P450 (CYP)-mediated hydroxylation at its tyrosol moiety and O-demethylation at its indomethacin moiety. Of the five major human CYPs, CYP3A4 and CYP2D6 catalyze the hydroxylation and O-demethylation reactions of PTI, respectively; whereas CYP1A2, 2C9 and 2C19 are inactive towards PTI. In contrast to PTI, indomethacin is primarily O-demethylated by CYP2C9, which prefers acidic substrates. The hydrolyzed and O-demethylated metabolites of PTI are further glucuronidated and sulfated, facilitating drug elimination and detoxification. We observed substantial inter-species differences in the metabolic rates of PTI. Among the liver microsomes from various species, PTI was the most rapidly hydrolyzed, hydroxylated and O-demethylated in mouse, human and rat liver microsomes, respectively. These results reflect the differential expression patterns of carboxylesterase and CYP isoforms among these species. Of the human microsomes from various tissues, PTI underwent more rapid carboxylesterase- and CYP-catalyzed reactions in liver and intestine microsomes than in kidney and lung microsomes. Together, our results establish the metabolic pathways of PTI, reveal significant inter-species differences in its metabolism, and provide insights into the underlying biochemical mechanisms.
authors: Division of Cancer Prevention, Department of Medicine, Stony Brook University, HSC, T17-080, Stony Brook, NY 11794, USA. basil.rigas@stonybrook.edu
authors: Gang
authors: G
authors: Xie
authors: Dingying
authors: D
authors: Zhou
authors: Ka-Wing
authors: KW
authors: Cheng
authors: Chi C
authors: CC
authors: Wong
authors: Basil
authors: B
authors: Rigas
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000378:metabolism*; D020719:Glucuronides / Q000378:metabolism; D006801:Humans; D066298:In Vitro Techniques; D007213:Indomethacin / Q000031:analogs & derivatives* / Q000378:metabolism; D007413:Intestinal Mucosa / Q000378:metabolism; D007668:Kidney / Q000378:metabolism; D008168:Lung / Q000378:metabolism; D051379:Mice; D008862:Microsomes, Liver / Q000378:metabolism; D010755:Organophosphates / Q000378:metabolism*; D051381:Rats
chemical_list: D000970:Antineoplastic Agents; D020719:Glucuronides; D010755:Organophosphates; C581098:phospho-tyrosol-indomethacin; D007213:Indomethacin
references: Expert Opin Drug Metab Toxicol. 2006 Dec;2(6):875-94
references: 17125407
references: Mol Nutr Food Res. 2009 Jul;53(7):897-903
references: 19685549
references: Xenobiotica. 1998 Dec;28(12):1203-53
references: 9890159
references: Exp Cell Res. 1996 Jan 10;222(1):179-88
references: 8549662
references: Cancer Res. 1981 May;41(5):1954-7
references: 7214363
references: Anaesthesia. 2006 Feb;61(2):159-77
references: 16430569
references: J Biol Chem. 1995 Dec 8;270(49):29055-8
references: 7493924
references: Biochem Pharmacol. 1999 Feb 15;57(4):445-9
references: 9933033
references: Br J Pharmacol. 2012 Jun;166(3):991-1001
references: 22141583
references: Cell. 2010 Mar 19;140(6):883-99
references: 20303878
references: Drug Metab Pharmacokinet. 2006 Oct;21(5):357-74
references: 17072089
references: J Pharmacol Exp Ther. 2012 Feb;340(2):422-32
references: 22085648
references: Drug Metab Dispos. 2008 Oct;36(10):2136-44
references: 18645035
references: Drug Metab Dispos. 2002 Mar;30(3):301-6
references: 11854149
references: Mol Carcinog. 1999 Aug;25(4):231-40
references: 10449029
references: Anticancer Res. 1998 Mar-Apr;18(2A):775-82
references: 9615719
references: Biochem Pharmacol. 2011 Dec 1;82(11):1781-91
references: 21840302
references: Br J Pharmacol. 2012 Sep;167(1):222-32
references: 22489789
references: Eur J Pharmacol. 1976 Jun;37(2):367-76
references: 954814
references: Molecules. 2008 Feb 18;13(2):412-31
references: 18305428
references: Neoplasia. 2007 Mar;9(3):222-35
references: 17401462
references: FASEB J. 1997 Jan;11(1):1-2
references: 9034159
references: Support Care Cancer. 2001 Sep;9(6):442-51
references: 11585271
references: Anal Chem. 2007 Nov 15;79(22):8720-7
references: 17944439
references: Carcinogenesis. 2013 Apr;34(4):943-51
references: 23338686
references: Drug Metab Dispos. 1998 Mar;26(3):261-6
references: 9492390
references: Nutr Cancer. 1996;25(3):231-40
references: 8771566
references: Carcinogenesis. 1983 Oct;4(10):1225-7
references: 6616752
references: Nutr Rev. 2005 Nov;63(11):374-86
references: 16370222
references: Mol Pharmacol. 2004 Apr;65(4):842-50
references: 15044613